Last Updated : May 21, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Ciprodex | Ciprofloxacin hydrochloride and dexamethasone otic suspension | Otitis media with otorrhea & otitis externa, acute | Do not list | Complete | ||
Clolar | clofarabine | Acute lymphoblastic leukemia | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Columvi | glofitamab | Relapsed or refractory diffuse large B-cell lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Combigan Ophthalmic Solution | Brimonidine tartrate/timolol maleate | Glaucoma | List with clinical criteria and/or conditions | Complete | ||
COMPLERA | Emtricitabine/ rilpivirine/ tenofovir disoproxil fumarate | HIV infection | List | Complete | ||
Constella | Linaclotide | Irritable bowel syndrome with constipation | Do not list | Complete | ||
Contrave | naltrexone hydrochloride and bupropion hydrochloride | Chronic weight management in adults | Do not reimburse | Complete | ||
Copaxone | Glatiramer acetate | Clinically Isolated Syndrome (CIS), suggestive of Multiple Sclerosis | Do not list | Complete | ||
Cortiment | Budesonide | Ulcerative Colitis | Do not reimburse | Complete | ||
Corzyna | ranolazine | Stable angina pectoris, adults | Do not reimburse | Complete |